Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $30 to $31.
November 03, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on ACADIA Pharmaceuticals and raised the price target from $30 to $31.
The news is directly related to ACADIA Pharmaceuticals and is likely to have a positive impact on its stock price in the short term. The increase in price target by a reputable financial institution like Morgan Stanley indicates a positive outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100